PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 13, 2026RSC Advances0 citationsOpen Access

Pyrazole/pyrimidine derivatives endowed with azobenzenes as dual EGFR T790M and VEGFR-2 inhibitors: anticancer, docking, synthesis, design and ADMET assessments

View Full Paper
KAKurls E. AnwerMAMohamed A. AbdelgawadFMFelemban Athary Abdulhaleem M

Key Points

  • This research aims to develop new derivatives targeting EGFR T790M and VEGFR-2 for cancer treatment.
  • Synthesis of pyrazole/pyrimidine derivatives using microwave and traditional methods.
  • Assessment of anticancer properties through docking studies.
  • Conducting ADMET (absorption, distribution, metabolism, excretion, toxicity) evaluations.
  • New derivatives exhibited significant inhibition of EGFR T790M and VEGFR-2.
  • Compounds showed promising anticancer activities in preliminary tests.
  • ADMET assessments indicated favorable profiles for further development.

Abstract

New pyrazole/pyrimidine derivatives endowed with azobenzenes were synthesized using microwave and traditional methods.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Anwer et al. (2026) studied this question.

synapsesocial.com/papers/69b3ad6c02a1e69014ccf702https://doi.org/10.1039/d5ra08997b
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design, synthesis and biological evaluation of Novel 6-azophenylcoumarin-3-formamido derivatives and a copper (II) complex2023 · 4 citations
  2. 2Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiencyin vitro2017 · 57 citations
  3. 3Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers2019 · 183 citations
  4. 4Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays1983 · 56,089 citations
  5. 5Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment2024 · 18 citations